Evidence map›Paper›PMID 38105258›Full record

ArticleInfectious diseases of poverty2023

Impact of 1,7-malaria reactive community-based testing and response (1,7-mRCTR) approach on malaria prevalence in Tanzania.

Wei Chang, Jessica Cohen, Duo-Quan Wang, Salim Abdulla, Muhidin Kassim Mahende, Tegemeo Gavana, Valerie Scott, Hajirani M Msuya, Mary Mwanyika-Sando, Ritha John A Njau and 19 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Infectious diseases of poverty, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

29 authors.

Wei ChangDepartment of Global Health and Population, Harvard T.H. Chan School of Public Health, Boston, MA, USA.
Jessica CohenDepartment of Global Health and Population, Harvard T.H. Chan School of Public Health, Boston, MA, USA.
Duo-Quan WangChinese Center for Disease Control and Prevention, National Institute of Parasitic Diseases, Shanghai, People's Republic of China.
Salim AbdullaIfakara Health Institute, #5 Ifakara Street, Plot 463 Mikocheni, P.O. Box 78 373, Dar es Salaam, United Republic of Tanzania.
Muhidin Kassim MahendeIfakara Health Institute, #5 Ifakara Street, Plot 463 Mikocheni, P.O. Box 78 373, Dar es Salaam, United Republic of Tanzania.
Tegemeo GavanaIfakara Health Institute, #5 Ifakara Street, Plot 463 Mikocheni, P.O. Box 78 373, Dar es Salaam, United Republic of Tanzania.
Valerie ScottDepartment of Global Health and Population, Harvard T.H. Chan School of Public Health, Boston, MA, USA.
Hajirani M MsuyaIfakara Health Institute, #5 Ifakara Street, Plot 463 Mikocheni, P.O. Box 78 373, Dar es Salaam, United Republic of Tanzania.
Mary Mwanyika-SandoAfrica Academy for Public Health, Dar es Salaam, Tanzania.
Ritha John A NjauMuhimbili University of Health and Allied Sciences, Dar es Salaam, Tanzania.
Shen-Ning LuChinese Center for Disease Control and Prevention, National Institute of Parasitic Diseases, Shanghai, People's Republic of China.
Silas TemuIfakara Health Institute, #5 Ifakara Street, Plot 463 Mikocheni, P.O. Box 78 373, Dar es Salaam, United Republic of Tanzania.
Honorati MasanjaIfakara Health Institute, #5 Ifakara Street, Plot 463 Mikocheni, P.O. Box 78 373, Dar es Salaam, United Republic of Tanzania.
Wilbald AnthonyAfrica Academy for Public Health, Dar es Salaam, Tanzania.
Maru Aregawi WGlobal Malaria Programme, World Health Organization, Geneva, Switzerland.
Naveen SunderBentley University, Waltham, MA, USA.
Tang KunVanke School of Public Health, Tsinghua University, Beijing, People's Republic of China.
Katia BruxvoortSchool of Public Health, University of Alabama at Birmingham, Birmingham, AL, USA.
Jovin KitauGlobal Malaria Programme, World Health Organization, Geneva, Switzerland.
Fadhila KihweleIfakara Health Institute, #5 Ifakara Street, Plot 463 Mikocheni, P.O. Box 78 373, Dar es Salaam, United Republic of Tanzania.
Godlove ChilaIfakara Health Institute, #5 Ifakara Street, Plot 463 Mikocheni, P.O. Box 78 373, Dar es Salaam, United Republic of Tanzania.
Mihayo MichaelIfakara Health Institute, #5 Ifakara Street, Plot 463 Mikocheni, P.O. Box 78 373, Dar es Salaam, United Republic of Tanzania.
Marcia CastroDepartment of Global Health and Population, Harvard T.H. Chan School of Public Health, Boston, MA, USA.
Nicolas A MenziesDepartment of Global Health and Population, Harvard T.H. Chan School of Public Health, Boston, MA, USA.
Sein KimDepartment of Global Health and Population, Harvard T.H. Chan School of Public Health, Boston, MA, USA.
Xiao NingChinese Center for Disease Control and Prevention, National Institute of Parasitic Diseases, Shanghai, People's Republic of China.
Xiao-Nong ZhouChinese Center for Disease Control and Prevention, National Institute of Parasitic Diseases, Shanghai, People's Republic of China.
Prosper ChakiIfakara Health Institute, #5 Ifakara Street, Plot 463 Mikocheni, P.O. Box 78 373, Dar es Salaam, United Republic of Tanzania.
Yeromin P MlachaIfakara Health Institute, #5 Ifakara Street, Plot 463 Mikocheni, P.O. Box 78 373, Dar es Salaam, United Republic of Tanzania. ymlacha@ihi.or.tz.ORCID http://orcid.org/0000-0001-8879-7066

Funding

World Health Organization 001
6 · The paper itself

Abstract

backgroundProgress in malaria control has stalled in recent years and innovative surveillance and response approaches are needed to accelerate malaria control and elimination efforts in endemic areas of Africa. Building on a previous China-UK-Tanzania pilot study on malaria control, this study aimed to assess the impact of the 1,7-malaria Reactive Community-Based Testing and Response (1,7-mRCTR) approach implemented over two years in three districts of Tanzania.

methodsThe 1,7-mRCTR approach provides community-based malaria testing via rapid diagnostic tests and treatment in villages with the highest burden of malaria incidence based on surveillance data from health facilities. We used a difference-in-differences quasi-experimental design with linear probability models and two waves of cross-sectional household surveys to assess the impact of 1,7-mRCTR on malaria prevalence. We conducted sensitivity analyses to assess the robustness of our results, examined how intervention effects varied in subgroups, and explored alternative explanations for the observed results.

resultsBetween October 2019 and September 2021, 244,771 community-based malaria rapid tests were completed in intervention areas, and each intervention village received an average of 3.85 rounds of 1-7mRCTR. Malaria prevalence declined from 27.4% at baseline to 11.7% at endline in the intervention areas and from 26.0% to 16.0% in the control areas. 1,7-mRCTR was associated with a 4.5-percentage-point decrease in malaria prevalence (95% confidence interval: - 0.067, - 0.023), equivalent to a 17% reduction from the baseline. In Rufiji, a district characterized by lower prevalence and where larviciding was additionally provided, 1,7-mRCTR was associated with a 63.9% decline in malaria prevalence.

conclusionsThe 1,7-mRCTR approach reduced malaria prevalence. Despite implementation interruptions due to the COVID-19 pandemic and supply chain challenges, the study provided novel evidence on the effectiveness of community-based reactive approaches in moderate- to high-endemicity areas and demonstrated the potential of South-South cooperation in tackling global health challenges.

Indexed as

MalariaPandemicsCross-Sectional StudiesHumansPilot ProjectsPrevalenceTanzania1,7-mRCTRCommunity-based testing and treatmentCommunity-health workerHealth facilityIncidence rateMalariaSurveillance and responseTanzania

Identifiers

PMID38105258
PMCPMC10726614

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.